IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical…


Previous articlePsychedelic Bulletin: MindMed Co-Founder Resigns from Board; Global Coalition to Reschedule Psilocybin Emerges; We Review Psychedelic Research and Trials from 2021
Next articlePsychedelic Research Bulletin: December 2021